<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628576</url>
  </required_header>
  <id_info>
    <org_study_id>VN 2003/15 (2-16-4 - 0001- 03)</org_study_id>
    <nct_id>NCT00628576</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities</brief_title>
  <official_title>Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg Universitetshospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate efficacy and safety of the new acute treatment of
      deep venous thrombosis by use of low-molecular-weight heparin compared with standard
      treatment using unfractionated heparin, especially concerning long-term morbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep-venous thrombosis (DVT) remains a common clinical problem (annual incidence 0.10-0.16%)
      and long-term morbidity as chronic venous insufficience (CVI) in 10-30%.

      As to recurrent DVT, initial treatment with Low-Molecular-Weight Heparin ( to-day's
      terminology Fractionated Heparin (FH)) and Unfractionated Heparin (UFH) has shown equal
      efficiency, whereas the efficacy concerning long-term morbidity has only more recently been
      published.

      This study was initiated to compare the efficacy of UFH and FH concerning the incidence of
      CVI after symptomatic DVT at short-term and long-term follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1993</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evaluation of chronic venous insufficiency (CVI) - (Postthrombotic Syndrome) based on internationally accepted criteria.</measure>
    <time_frame>Two years and 6 to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UFH: patients treated with unfractionated heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FH: patients treated with low-molecular-weight (fractionated) heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated heparin</intervention_name>
    <description>UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Heparin SAD 1000 IU/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin (Leo)</intervention_name>
    <description>FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Innohep (Leo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First DVT with or without known risk factors except overt cancer

          -  Second DVT more than two years after the first if the patient was without clinical
             signs of CVI.

        Exclusion Criteria:

          -  Contraindication to anticoagulation therapy

          -  Candidate to thrombectomy with arterious-venous fistula or thrombolytic therapy

          -  Known cancer at the time of the DVT diagnosis

          -  Patients unable to cooperate for anticoagulation therapy or manage the tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedicte Laursen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haematology; Aalborg Hospital, 9100 Aalborg, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Haematology; Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Region Nordjylland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>February 26, 2008</last_update_submitted>
  <last_update_submitted_qc>February 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Principal investigator: Benedicte Laursen MD, DMSc</name_title>
    <organization>Department of Haematology and Medicine Aalborg Hospital, 9100 Aalborg, Denmark</organization>
  </responsible_party>
  <keyword>Deep Venous Thrombosis</keyword>
  <keyword>lower extremities</keyword>
  <keyword>Chronic Venous Insufficiency</keyword>
  <keyword>Postthrombotic Syndrome</keyword>
  <keyword>Heparins</keyword>
  <keyword>Low-molecular- weight heparin</keyword>
  <keyword>Tinzaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

